Donna Roy Grogan - 02 Jan 2026 Form 4 Insider Report for C4 Therapeutics, Inc. (CCCC)

Role: Director
Signature: /s/ Jolie M. Siegel, Attorney-in-Fact
Issuer symbol: CCCC
Transactions as of: 02 Jan 2026
Net transactions value: +$14,500
Form type: 4
Filing time: 05 Jan 2026, 16:10:26 UTC
Previous filing: 03 Oct 2025
SEC: View on sec.gov

Reporting Owners (1)

Name	Relationship	Address	Signature	Signature date	CIK
GROGAN DONNA ROY	Director	C/O C4 THERAPEUTICS, INC., 490 ARSENAL WAY #120, WATERTOWN	/s/ Jolie M. Siegel, Attorney-in-Fact	05 Jan 2026	0001788455

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	CCCC	Common Stock	Award	$14,500	+7,513	+13%	$1.93	66,142	02 Jan 2026	Direct	F1, F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	These shares were issued in accordance with the Issuer's Non-Employee Director Compensation Policy, pursuant to which the Reporting Person elected to receive shares of the Issuer's common stock in lieu of cash compensation for services as a non-employee director of the Issuer.
F2	The price reported in Column 4 is based upon the closing market price of the Issuer's common stock on January 2, 2026.